Included in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreTopics covered include are payers helping or hindering biosimilar market access as well as can MCDA ...
Read moreTopics include our perspectives on an EU commission report on how international reference pricing ca...
Read moreIncluded is the P&R challenges faced by the PCSK9 inhibitors as well as how payers are trying to ove...
Read moreIn this issue is an overview of the future changes to the UK Cancer Drug Fund as well as approaches ...
Read moreAn update on UK market access at EUCOPE meeting
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read more